StreetInsider.com News Articles

Elutia to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026

Thu, 22 Oct 2026 16:05:00 -0400

GAITHERSBURG, Md., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its third quarter 2026 financial results after market close on Thursday, November 5, 2026. Members of the Company’s management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day.

The conference call can be accessed using the following information:

Webcast: Click here

Dial-In: Click here

Elutia to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026

Thu, 22 Oct 2026 16:05:00 -0400

The conference call can be accessed using the following information:

Webcast: Click here

Dial-In: Click here

Elutia receives $8M escrow payment from Boston Scientific

Thu, 01 Oct 2026 16:49:55 -0400

Elutia Inc. (Nasdaq: ELUT) announced it has received an $8 million escrow payment from Boston Scientific Corporation (NYSE: BSX), completing a holdback period tied to the October 2025 sale of its BioEnvelope business for $88 million.

The payment was released with no indemnity claims following the one-year holdback period. Elutia said the company is now funded through the first full year of its planned NXT-41x commercial launch and into 2029, without the need for an equity offering.

The escrow release is the third of three funding milestones the company outlined in its second quarter earnings release. The other two were the closing

Elutia receives $8M escrow payment from Boston Scientific

Thu, 01 Oct 2026 16:49:55 -0400

The escrow release is the third of three funding milestones the company outlined in its second quarter earnings release. The other two were the closing

Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029

Thu, 01 Oct 2026 16:45:00 -0400

Boston Scientific released the full $8 million holdback on schedule and with no claims
Escrow release is the third funding catalyst Elutia has delivered in 2026, following the August closings of its Avenue Capital loan facility and SimpliDerm® divestiture
The Company is now fully funded through the first year of the expected NXT-41x launch and into 2029

GAITHERSBURG, Md., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced it has received the full $8 million held in escrow in connection with the sale

Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029

Thu, 01 Oct 2026 16:45:00 -0400

Boston Scientific released the full $8 million holdback on schedule and with no claims
Escrow release is the third funding catalyst Elutia has delivered in 2026, following the August closings of its Avenue Capital loan facility and SimpliDerm® divestiture
The Company is now fully funded through the first year of the expected NXT-41x launch and into 2029

Form 4 ELUTIA INC. For: Sep 10 Filed by: Ferguson Matthew

Mon, 14 Sep 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260914/27059163.html

Form 4 ELUTIA INC. For: Sep 10 Filed by: Williams Michelle LeRoux

Mon, 14 Sep 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260914/27059156.html

Form 4 ELUTIA INC. For: Sep 10 Filed by: Mills C Randal

Mon, 14 Sep 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260914/27059147.html

Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th

Thu, 10 Sep 2026 16:05:00 -0400

GAITHERSBURG, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer; Dr. Michelle Williams, Chief Scientific Officer; and Matthew Ferguson, Chief Financial Officer, will present and host one-on-one meetings with investors at the H.C. Wainwright 28th Annual Global Investment Conference at the Lotte New York Palace Hotel in New York City on September 15–16, 2026.

During the presentation, management will discuss how Elutia is working to address post-surgical infection in plastic and reconstructive surgeries—one of the

Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th

Thu, 10 Sep 2026 16:05:00 -0400

During the presentation, management will discuss how Elutia is working to address post-surgical infection in plastic and reconstructive surgeries—one of the

Form 8-K ELUTIA INC. For: Aug 17

Fri, 21 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260821/26962310.html

Form 8-K ELUTIA INC. For: Aug 17

Fri, 21 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260821/26962310.html

Cellution Biologics buys SimpliDerm from Elutia for up to $11M

Tue, 18 Aug 2026 11:19:53 -0400

Cellution Biologics Inc. has completed its acquisition of the SimpliDerm hydrated human acellular dermal matrix business from Elutia Inc. (Nasdaq: ELUT), according to a press release from the company.

Under the terms of the deal, Cellution Biologics paid $8 million at closing, subject to agreed adjustments, with up to an additional $3 million in transition and commercial milestone payments over the following 18 months.

SimpliDerm is a hydrated human acellular dermal matrix designed for soft tissue repair and reconstruction, available in a range of configurations and sizes. The product has an existing commercial presence in the U.S. reconstructive surgery market, including established

Cellution Biologics buys SimpliDerm from Elutia for up to $11M

Tue, 18 Aug 2026 11:19:53 -0400

Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc.

Tue, 18 Aug 2026 11:19:00 -0400

ROSWELL, Ga., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Cellution Biologics Inc. (“Cellution Biologics” or the “Company”), a biologics company focused on developing, manufacturing and commercializing advanced human tissue-based products, today announced the completion of its acquisition of the SimpliDerm hydrated human acellular dermal matrix (ADM) business from Elutia Inc. (Nasdaq: ELUT).

The acquisition marks Cellution Biologics’ entry into the U.S. reconstructive surgery market, adding a new surgical category to its existing portfolio across wound care, ocular repair and other surgical applications. SimpliDerm is an established human acellular dermal matrix with a proven commercial presence in

Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc.

Tue, 18 Aug 2026 11:19:00 -0400

Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc.

Tue, 18 Aug 2026 11:19:00 -0400

Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc.

Tue, 18 Aug 2026 11:19:00 -0400

Elutia sells SimpliDerm unit for up to $11M to fund NXT-41x

Tue, 18 Aug 2026 08:00:37 -0400

Elutia Inc. (Nasdaq: ELUT) has completed the sale of its SimpliDerm human acellular dermal matrix business to Cellution Biologics Inc. for total consideration of up to $11 million, according to a company statement.

The deal includes $8 million paid at closing, subject to adjustments for inventory levels and transaction expenses, plus up to $3 million in contingent milestone payments over the next 18 months.

Elutia said the proceeds represent non-dilutive capital that, combined with previously announced funding sources, the company believes is sufficient to support operations through the first full year of commercial launch of its NXT-41x product in 2028.

NXT-41x is an

Elutia sells SimpliDerm unit for up to $11M to fund NXT-41x

Tue, 18 Aug 2026 08:00:37 -0400

The deal includes $8 million paid at closing, subject to adjustments for inventory levels and transaction expenses, plus up to $3 million in contingent milestone payments over the next 18 months.

NXT-41x is an

Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch

Tue, 18 Aug 2026 08:00:00 -0400

Deal valued at $11 million in cash, with $8 million at closing and up to $3 million in additional milestone payments over the next 18 months
Divestiture further concentrates Elutia’s attention and resources on the development and commercialization of NXT-41x
NXT-41x is an antibiotic-eluting biomatrix designed to address post-operative infection in the $1.5 billion U.S. plastic and reconstructive surgery market
NXT-41x clearance expected in the first half of 2027

GAITHERSBURG, Md., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced

Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch

Tue, 18 Aug 2026 08:00:00 -0400

Deal valued at $11 million in cash, with $8 million at closing and up to $3 million in additional milestone payments over the next 18 months
Divestiture further concentrates Elutia’s attention and resources on the development and commercialization of NXT-41x
NXT-41x is an antibiotic-eluting biomatrix designed to address post-operative infection in the $1.5 billion U.S. plastic and reconstructive surgery market
NXT-41x clearance expected in the first half of 2027

GAITHERSBURG, Md., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced

Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch

Tue, 18 Aug 2026 08:00:00 -0400

Deal valued at $11 million in cash, with $8 million at closing and up to $3 million in additional milestone payments over the next 18 months
Divestiture further concentrates Elutia’s attention and resources on the development and commercialization of NXT-41x
NXT-41x is an antibiotic-eluting biomatrix designed to address post-operative infection in the $1.5 billion U.S. plastic and reconstructive surgery market
NXT-41x clearance expected in the first half of 2027

GAITHERSBURG, Md., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced

Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch

Tue, 18 Aug 2026 08:00:00 -0400

Deal valued at $11 million in cash, with $8 million at closing and up to $3 million in additional milestone payments over the next 18 months
Divestiture further concentrates Elutia’s attention and resources on the development and commercialization of NXT-41x
NXT-41x is an antibiotic-eluting biomatrix designed to address post-operative infection in the $1.5 billion U.S. plastic and reconstructive surgery market
NXT-41x clearance expected in the first half of 2027

GAITHERSBURG, Md., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced